New hope for hard-to-treat bile duct cancer: drug duo targets KRAS mutation

NCT ID NCT05874414

First seen Nov 01, 2025 · Last updated Apr 25, 2026 · Updated 20 times

Summary

This study tests a new combination of two drugs, GNS561 and trametinib, in people with advanced bile duct cancer that has a specific genetic change called a KRAS mutation. The cancer must have worsened after at least one round of standard chemotherapy. The goal is to see if the combination is safe and can shrink tumors. About 74 adults will take part in this early-phase trial.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHOLANGIOCARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Froedtert Hospital and the Medical College of Wisconsin

    RECRUITING

    Milwaukee, Wisconsin, 53226, United States

    Contact

  • Hospital of the University of Pennsylvania

    TERMINATED

    Philadelphia, Pennsylvania, 19104, United States

  • LA Cancer Network

    RECRUITING

    Los Angeles, California, 92801, United States

    Contact

  • Moffitt Cancer Center

    RECRUITING

    Tampa, Florida, 33612, United States

    Contact

  • Orlando Health

    RECRUITING

    Orlando, Florida, 32806, United States

    Contact

  • Pan American Center for Oncology Trials, LLC

    RECRUITING

    Rio Piedras, Puerto Rico, 00935, Puerto Rico

    Contact

  • Roswell Park Cancer Institute

    TERMINATED

    Buffalo, New York, 14263, United States

  • USC Norris Comprehensive Cancer Center

    RECRUITING

    Los Angeles, California, 90033, United States

    Contact

  • University Of Chicago Medical Center

    RECRUITING

    Chicago, Illinois, 60637, United States

    Contact

  • University of Texas, MD Anderson Cancer Center

    RECRUITING

    Houston, Texas, 77030, United States

    Contact

  • University of Virginia Comprehensive Cancer Center

    RECRUITING

    Charlottesville, Virginia, 22908, United States

    Contact

Conditions

Explore the condition pages connected to this study.